Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - An area of leishmania (V.) braziliensis transmission

International Journal of Dermatology

Volumn 36, Issue 6, 1997, Pages 463-468

  Oliveira Neto, Manuel P ^a   Schubach, Armando ^a   Mattos, Marise ^a   Gonçalves Da Costa, Sylvio C ^a   Pirmez, Claude ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; MEGLUMINE;

ADULT; ARTICLE; BRAZIL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALE; SKIN LEISHMANIASIS; ULCER HEALING;

EID: 0030742919     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1997.00188.x     Document Type: Article

References (39)

1. Grimaldi G, Tesh RB, McMahon-Pratt D. A review of geographic distribution and epidemiology of leishmaniasis in New World. Am J Trop Med Hyg 1989; 41: 687-72.5.
2. WHO. The Leishmaniasis. Technical Report Series 1984; 701: 1-140.
3. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 196-306.
4. Marsden P. New light on pentavalent antimonials in the treatment of leishmaniasis. Rev Soc Bras Med Trop 1983; 16: 172-174.
5. Evans TG. Leishmaniasis. Infect Dis Clin North Am 1993; 7: 52-7-546.
6. Lopes UG, Momen H, Grimaldi G, et al. Schizodeme and zymodeme characterization of Leishmania. The investigation of foci of visceral and cutaneous leishmaniasis. J Parasitol 1984; 70: 89-98.
7. Grimaldi G, David JR, McMahon-Pratt D. Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg 1987; 36: 270-287.
8. el Darouti MA, al Rubaie SM. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intra lesional stibogluconate injection. Int J Dermatol 1990; 29: 56-59.
9. Faris RM, Jarallah JS, Khoja TA, et al. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32: 610-612.
10. Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119: 53-57.
11. Cohen H, Livshin R. Treatment of leishmaniasis nodosa (oriental sore) with intralesionally injected emetine hydrochloride. J Am Acad Dermatol 1987; 17: 595-599.
12. Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165: 528-534.
13. WHO. The Leishmaniasis. Technical Report Series 1990; 793: 59-62.
14. Balzan M, Fenech F. Acute renal failure in visceral leishmaniasis treated with sodium stibogluconate. Trans R Soc Trop Med Hyg 1992; 86: 515-516.
15. Chulay J, Spencer H, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34: 702-709.
16. Hepburn NC, Siddique I, Howie AF, et al. Hepatotoxicity of sodium stibogluconate in leishmaniasis [letter]. Lancet 1993; 342: 138-239.
17. Hepburn NC, Nolan J, Fenn L, et al. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. QJM 1994; 87: 465-472.
18. Gasser RA, Jr., Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18: 83-90.
19. Antezana G, Zeballos R, Mendoza C, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86: 31-33.
20. Horber FF, Lerut J, Jaeger P. Renal tubular acidosis, a side effect of treatment with pentavalent antimony [letter]. Clin Nephrol 1991; 36: 213.
21. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113: 934-940.
22. Cucê LC, Belda Junior W, Dias MC. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case]. Rev Inst Med Trop São Paulo 1990; 31: 249-251.
23. Oliveira-Neto MP, Pirmez C, Rangel E, et al. An oubtreak of American cutaneous leishmaniasis (Leishmania braziliensis braziliensis) in a periurban area of Rio de Janeiro city, Brazil. Clinical and epidemiological studies. Mem Inst Oswaldo Cruz 1988; 84: 427-435.
24. Rangel E, Azevedo ACR, Andrade CA, et al. Studies on sandfly fauna (Diptera: Psychodidae) in a focus of cutaneous leishmaniasis in Mesquita, Rio de Janeiro state, Brazil. Mem Inst Oswaldo Cruz 1990; 85: 39-45.
25. Solano EA, Hidalgo HH, Zeledon AR. Tratamiento intralesional exitoso de la leishmaniasis por Leishmania braziliensis panamensis con Glucantime. Med Cut I L A 1984; 12: 19-2.4.
26. Gadelha AR, Olivera WC, Assunção IJ, et al. Tratamento da leishmaniose tegumentar americana com injeções intralesionais de n-metil glucamina. Ann Bras Dermatol 1995; 65: 201-2.03.
27. Barrios L, Costa J,. Netto E, et al. Intralesional Glucantime in Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 1986; 80: 173-174.
28. Marsden P, Llanos Cuentas E, Lago E, et al. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia, Brasil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev So Bras Med Trop 1984; 17: 179-186.
29. Sampaio RNR, Marsden PD, Furtado T, et al. Avaliação do tratamento da leishmaniose cutâneo-mucosa com três esquemas diferentes de antimoniais pentavalentes. Ann Bras Dermatol 1989; 64: 189-192.
30. Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrobial Agents Chemotherapy 1985; 27: 916-920.
31. Chulay J, Fleckenstein L, Smith D. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988; 82: 69-72.
32. Rees P, Keating M, Kager P, et al. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980; 2: 226-229.
33. Duperrat B, Puissant A, Fischer R, et al. Leishmaniose cutanée pluri-focale traitée par glucantime intralesionelle. Bull Soc Fr Derm Syph 1966; 73: 219-220.
34. Pirmez C, Yamamura M, Uyemura K, et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin Invest 1993; 91: 1390-1395.
35. Mendonça SC, Coutinho SG, Amendoeira RR, et al. Human American cutaneous leishmaniasis (Leishmania braziliensis braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64: 269-276.
36. Mendonça S, Souza W, Nunes M, et al. Indirect immunofluorescence test in New World leishmaniasis: serological and clinical relationship. Mem Inst Oswaldo Cruz 1988; 83: 347-355.
37. Cuba-Cuba CA, Evans D, Rosa AC, et at. Clonal variation within a mucosal isolate derived from a patient with Leishmania (Viannia) braziliensis infection. Rev Inst Med Trop São Paulo 1991; 33: 343-350.
38. Saravia NG, Holguin AF, McMahon-Pratt D, et al. Mucocutaneous leishmaniasis in Colombia: Leishmania braziliensis subspecies diversity. Am J Trop Med Hyg 1995; 34: 714-720.
39. Weigle KA, Saravia NG, Davalos M, et al. Leishmama braziliensis from the pacific coast region of Colombia: foci of transmission, clinical spectrum and isoenzyme phenotypes. Am J Trop Med Hyg 1996; 35: 722-731.